Dublin, Ireland, October 30, 2014
Inflection Biosciences Ltd, a private company developing targeted small molecule treatments for cancer, today announced a research collaboration with Trinity College Dublin. The collaboration is being led by Dr. Kathy Gately, Clinical Lecturer Thoracic Oncology Research at the Institute of Molecular Medicine, St. James’s Hospital Dublin.
Dr. Kathy Gately’s team will examine the effectiveness of a panel of the company’s targeted kinase inhibitors in laboratory tests to demonstrate the effectiveness of these new compounds in the treatment of cancer. In particular Dr. Gately’s work focuses on solid tumours that have become resistant to other forms of treatment.
Dr. Kathy Gately commented “Our research is focused on how the cancer cell develops mechanisms of resistance to treatment which leads to cancer progression. The Inflection Biosciences’ compounds target key pathways in cancer cells which make them able to resist the effects of chemotherapy. By shutting down these pathways the compounds not only kill cancer cells but can stop them developing resistance. For patients this means a prolonged response to treatment”
This research is supported in part by a Feasibility Study Grant from Enterprise Ireland’s Innovation Partnership Program which is aimed at helping Irish companies conduct cutting edge research by collaborating with Ireland’s leading scientific experts.
Dr. Michael O’Neill, Director of Research and Development at Inflection Biosciences Ltd added “Dr. Gately and the Thoracic Oncology Group at St. James’s Hospital are recognized as world leaders in this research. We are delighted to be able to work with her to develop our programs. We are now well positioned to assess the potential of our programs in difficult to treat cancers where the need is so great”
About the Institute of Molecular Medicine, Trinity College Dublin
The research interests of the Institute of Molecular Medicine (IMM) are centred on Trinity College Dublin’s research strategy, which focuses primarily on cancer and inflammation. Trinity, founded in 1592, is Ireland’s oldest university and today has a vibrant community of 17,000 students. It is recognised internationally as Ireland’s premier university. Cutting edge research, technology and innovation places the university at the forefront of higher education in Ireland and globally. It encompasses all major academic disciplines, and is committed to world-class teaching and research across the range of disciplines in the arts, humanities, engineering, science, social and health sciences. Trinity is Ireland’s leading university across all international rankings, and is ranked 61st globally in the 2013 QS World University Ranking. For further information please visit Trinity’s website at www.tcd.ie.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises a unique dual mechanism pan-PIM/PI3 kinase inhibitor program and a pan-PIM kinase inhibitor program, both in preclinical development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. For more information please visit the Company’s website at www.inflectionbio.com
Comments